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a  b  s  t  r  a  c  t
The  Human  Papilloma  Virus  (HPV)  is  a causal  agent  in  a  subset  of Head  and  Neck Cancers  (HNC),  which is
being  diagnosed  in  younger  men  without  a signiﬁcant  history  of tobacco  and  alcohol  use.  The increasing
incidence  of these  cancers  and the burgeoning  cost  associated  with  treatment  should  make this  issue a
legitimate  oncopolicy  agenda  priority.  This  communication  details  a number  of  actionable  strategies  that
policy-makers  could  implement  to reduce  the  number  of  people  diagnosed  with  the  disease,  enhance
the  quality  of life  for  those  living  with  the  disease  and  lessen  the  likelihood  of dying  from  the disease.
Based on  a  HPV  and Head  and  Neck  Cancer  symposium  held  in  National  University  of  Ireland,  Galway
on  May  17th  2013.  We  make  the argument  that  a supra-regional,  multidisciplinary,  research-focused
approach  to HPV-related  HNC  is  urgently  needed.  Policy-makers  could  support  a network  of  researchers
in  the  ﬁelds  of epidemiology,  pathology,  clinical  treatment,  health  economics  and  public  health  to  work
together  to raise  public  awareness  about  the disease,  treat  patients  to  the  highest  international  stan-
dards and  evaluate  prevention  strategies  such  as gender-neutral  HPV  vaccination.  We  hope  that  this
 sway
 201communication  will  hold
©
ackground and context
The seminal paper linking HPV and a subset of Head and Neck
ancers (HNC) was published relatively recently in 2000 [1]. The
ymphoepithelium of the oropharynx (i.e. Base of tongue, Waldyer’s
ing, tonsillar fossa and lingual tonsils) is the primary site for
PV-related HNC. These cancers have been accepted as a distinct
pidemiologic, clinical, and molecular entity [2]. Comparison of the
nown epidemiology of HPV-related and unrelated HNC is given in
able 1.
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In the US, the latest estimated annual incident cases of HPV-
associated HNC (∼12,989) have now surpassed cervical cancer
(∼11,388) and look set to increase [4]. In France, the estimated
annual costs of treating HPV-associated HNC in men  (D94.6million)
is greater than invasive cervical cancer (D83.9million) in women
[5]. Many unanswered questions remain about the natural history
of these cancers, how best to treat HPV-positive HNC and the effec-
tiveness of HPV prophylactic vaccines against oral HPV infection [6].
The actionable content that follows outlines practical policy rec-
ommendations in different disciplines to counter the rise of these
cancers.
Epidemiology
The Korean cancer registry is the latest group to report trends
in population-level HPV-related HNC sites based on International
Classiﬁcation of Disease (ICD) codes [7]. A more costly and scien-
Open access under CC BY-NC-ND license.tiﬁc approach, adopted in Ireland, involves retrospective analysing
archival tissue samples for HPV. Either epidemiologic approach
provides ‘baseline’ information to policy-makers regarding the
likely burden of this disease in their jurisdiction.
icense.
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Table 1
Comparison of the general epidemiology of HPV related and unrelated Head and
Neck Cancers (HNC) [3].
HPV-related HNC HPV-unrelated
HNC
Incidence trend Increasing Decreasing/stable
Anatomic location Primarily tonsil
and base of tongue
All head and neck
sites
Median age (year) at diagnosis 54 60
Socioeconomic status Higher Lower
Primary risk factors Sexual exposure to
oral HPV
Tobacco and
alcohol exposure
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3-Year oropharyngeal survival (%) 82 57
The prevalence of oral HPV at population level was recently
stimated in the US by utilizing an established national represen-
ative survey – National Health and Nutrition Examination Survey
NHANES) [8]. Survey participants gargled a 30-second oral rinse
hat underwent HPV DNA analysis. The results showed that 6.9% of
dults and teenagers (14–69 years) were infected with oral HPV of
ny kind. Only 1% of the population was infected with HPV-16, the
train most linked to oropharyngeal and cervical cancer. Oral HPV
nfection was three times more prevalent in men  than in women,
ovetailing with the rate of HPV-related oropharyngeal cancers
ow seen in the US. Stratifying the data by age shows a bimodal
istribution with peaks in individuals aged 30 to 34 years (7.3%;
5% CI, 4.6–11.4%) and 60 to 64 years (11.4%; 95% CI, 8.5–15.1%).
Without the appropriate population-level research vehicle to
ollect oral rinses and test for HPV, researchers, like those in Scot-
and, are embarking on prevalence feasibility study using dental
ractices. We  recommend that any oral HPV prevalence study be
epeated periodically to help establish the natural history of the
nfection and estimate the impact HPV vaccination has on the
revalence of oral HPV.
athology
In 2011, the College of American Pathologists and the American
oint Committee on Cancer added routine HPV testing as part of
he standard pathologic evaluation of resected oropharyngeal squa-
ous cell carcinomas (OPSCC) for the purpose of molecular tumour
taging. HPV testing of clinical samples is useful for establishing the
ite of tumour origin for patients presenting with metastatic dis-
ase, for guiding therapy, for educating/counselling patients, and
or estimating clinical outcomes [9]. Indeed, HPV-positive OPSCC
s associated with signiﬁcantly lower all-cause and cancer spe-
iﬁc mortality adjusting for covariates and detection methods [10].
herefore, HPV status is now recognized as the most important
ndependent prognostic variable.
There is currently no standard approach for HPV testing of
linical samples. Instead, methods of HPV testing across labo-
atories vary considerably reﬂecting the biases and tendencies
f individual investigators. Detection strategies vary not just in
esign, but in their detection targets. These targets have included
PV DNA, HPV RNA, viral oncoproteins, cellular proteins and
PV-speciﬁc serum antibodies. For widespread implementation in
he clinical arena, detection methods must be accurate, technically
easible and cost-effective. Most laboratories use 1 of the 2 HPV
NA detection methods – Polymerase Chain Reaction (PCR)-based
mpliﬁcation or In Situ Hybridization (ISH). Immunostaining for
16 protein has recently been regarded as a practical alternative
r complementary procedure for HPV testing of oropharyngeal
ancers based on a high correlation between the HPV detection
nd p16 overexpression in recent studies. Indeed, the simplicity,
ow cost and high sensitivity of p16 immunohistochemistry havePolicy 1 (2013) e49– e51
prompted consideration of replacing more intensive ISH and
PCR-based methods as a standalone HPV test.
The successful development of detection assays optimized for
cytological samples [e.g. ﬁne-needle aspirations (FNA) of neck
metastases using liquid phase assays (e.g. Hybrid Capture 2 assay)]
will open the door to more widespread implementation of HPV test-
ing, and may  obviate expensive tissue acquisition and processing
[11]. A multi-centred trial of the clinical and cost-effectiveness of
FNA in an outpatient/clinic care setting seem warranted. Moreover,
it is imperative that HPV testing of OPSCC be routinely conducted.
Policy-makers should encourage that standardized HPV pathology
guidelines be implemented in hospitals treating OPSCC patients.
Work-up, clinical trials and treatment
The work-up of a suspected HPV-related HNC patient should
include detailed patient history (i.e. presenting symptoms, risk
proﬁle), physical examination (i.e. primary site inspection and pal-
pation, neck nodules, radiography) and biopsy (i.e. examination
under anaesthesia and HPV testing) [12]. Development of a work-
up checklist system would ensure that universal standards of care
would occur across various regional treatment centres. It would be
prospectively appropriate for cancer registries to record HPV/p16
status along with other health behaviours such as smoking and
alcohol use for all HNC patients.
Currently, HPV-positive and negative OPSCC are treated sim-
ilarly even though they are very different diseases. Treatment
options are usually multimodality that includes laser/robotic
surgery, radiation and various chemotherapy agents. To categor-
ically avoid biases, growing consensus among cancer investigators
exists to support the opening of phase II/III trials that strictly
study either HPV-positive disease or HPV-negative disease [13].
The favourable responsiveness of HPV-positive OPSCC to current
treatment represents an exciting opportunity for studying careful
treatment deintensiﬁcation to reduce acute toxicity and improve
long-term patient recovery. We  recommend that cost and func-
tional outcomes/quality of life research form part of the trial design
to inform evidence-based policy making.
While awaiting the results of large US studies (e.g. E1308 & RTOG
1016) and UK studies (e.g. De-ESCLaTE HPV, REALISTIC), a model of
shared decision-making could be promoted by policy-makers. This
model of care, advocated by Johns Hopkins Hospital, encourages
patients to meet with head and neck surgeons, medical oncolo-
gists, radiation oncologists, and speech language pathologists in
one clinic visit. After review of medical records, pathology, imaging
studies and physical examination, a consensus opinion regarding
management is given. This process of shared decision-making gives
the patient and his/her caregivers the opportunity to openly discuss
pros and cons of various treatment and management options with
all disciplines present.
Public awareness of HPV-associated HNC
In June 2013, Hollywood actor, Michael Douglas, in a candid
interview with the Guardian newspaper in England, made refer-
ence to HPV as a causal agent in HNC. The interview created a large
media attention on the risk factors (i.e. oral sex) involved in HPV-
associated HNC. A legacy of the ‘Michael Douglas’ media story is
to address the social stigma associated with HPV. As an infection
spread by intimate contact, HPV is ubiquitous among the sexually
active. The reason why only a very small proportion of infected indi-
viduals go on to develop HPV-related HNC are currently unknown,
but complex interactions between the virus and the host immune
system appear to play very important roles. In the emerging social
media era, we recommend that each jurisdiction develop a public
health campaign that uses video and infographics to convene their
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essage in the social media era [14]. Mount Sinai Medical Center,
ew York produced an excellent infographic entitled: “Can I get
ancer from oral sex?”
Patient-led interest groups like the Throat Cancer Foundation
n Scotland and HPVandme.org in San Francisco have emerged
ecently to raise awareness of HPV and HNC. Many more survivors
f this cancer are bravely sharing their stories in various media out-
ets and actively campaigning for more research into treating and
reventing this form of cancer.
arly detection and prevention strategies
Cervical cancer screening is effective in detecting precan-
erous lesions caused by HPV. Given the inaccessibility of the
ropharynx and lack of known precancerous lesions, a similar
creening technique is more difﬁcult to perform for suspected HPV-
elated HNC. Encouragingly, early detection may  be possible by
 blood test. Using the European Prospective Investigation into
ancer and Nutrition cohort, investigators showed that HPV16 E6
eropositivity was present more than 10 years before diagnosis of
ropharyngeal cancers [15].
Public health practitioners are genuinely optimistic that HPV
accination will prevent future HPV-associated cancers. In 2013,
olicy-makers in Australia added boys to their school-wide HPV
accination programme. However, an opposing polemic develop-
ent occurred in Japan, as the Health Ministry withdrew support
or the vaccine to implement investigations into its safety. Cur-
ently in Europe, HPV vaccinations are not licensed for cancer
revention in males. Pharmaceutical manufacturers are likely to
eek reimbursement for cancer prevention in males and for future
ealth technology assessment of gender-neutral HPV vaccination;
etailed HPV-associated HNC cost-of-care studies are needed to
ssess the cost-effectiveness of vaccinating both sexes. As politics
lay a critical role in health policy formation, HPV vaccination in
irls has already been a contentious issue in many countries. We’d
ncourage ‘open’ debate with a consultation process. However, a
trong emphasis on scientiﬁc evidence ought to inform decision-
aking and this communication sets out a number of key studies
o gather such vital information.onclusion
We  strongly feel that within each patient is an opportunity to
earn more about this emerging disease. Clinicians should not only
able 2
roposed multi-disciplinary policy initiatives.
Discipline Achievable policy initiatives
Epidemiology • Retrospective analysis of sample tissue for HPV in
associated HNC sites
• Oral HPV prevalence studies
Pathology • Routine testing of oropharyngeal cancer for HPV &
p16 biomarker
• Standardisation of HPV detection methods
• Prospective HPV/p16 status recording by registries
• Funding to determine the cost-effectiveness of using
Fine Needle Aspiration (FNA) for early detection
Clinical management • Standard work-up checklist for HNC Physicians
•  Enrol patients in clinical trials and functional
outcome studies
•  Shared decision-making with patient involvement
Health economics • Cost-of-care study of HPV-related HNC
• Gender neutral HPV vaccination evaluation
Public health • Investment in an awareness campaign
•  Primary care education of signs and symptoms
•  ‘Open’ consultation process with medical
organisations, advocacy groups, faith organisations,
pharmaceutical industry and other stakeholders to
implement policy
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treat the patient but also advance the ﬁeld by enrolling patients into
clinical trials or functional outcome studies. Moreover, we believe
that supportive oncopolicy of multidisciplinary collaboration (See
Table 2) can make a huge difference in tackling this potentially
modiﬁable disease.
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